Recce Pharmaceuticals (ASX:RCE) said it is nearing the completion of its second phase clinical trial of RECCE 327 Topical Gel (R327G), targeting acute bacterial skin and skin structure infections, with 20 out of 30 patients dosed, according to a Tuesday filing with the Australian bourse.

The study showed that all patients who completed R327G treatment met the primary endpoints of the study, either cured or with notable improvement, with no reported serious adverse events, the filing said.

The patient dosing is expected to be completed within the year, according to the filing.